

Publications

Publications produced by the RMLM (1993-2008) including only those directly as a result of work done in the centre, or concepts derived from its work.

1. Moore CB, Law D, Denning DW. *In vitro* activity of the azole D0870 against *Aspergillus* spp compared with amphotericin B and itraconazole. **J Antimicrob Chemother** 1993;32:831-836.
2. Law D, Moore CB, Denning DW. A new bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. **Antimicrobial Agents Chemother** 1994; 38: 1561-1566.
3. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MGL, Denning DW. High prevalence of antifungal resistance in *Candida* spp. from patients with AIDS. **J Antimicrob Chemother** 1994; 34: 659-668.
4. Ng TC, Campbell CK, Rothera M, Houghton JB, Hughes D, Denning DW. Successful therapy of sinus zygomycosis caused by *Cunninghamella bertholletiae*, without surgery. **Clin Infect Dis** 1994; 19: 313-316.
5. Wardle H, Moore C, Law D, Mason C, Denning DW. In vitro activity of D0870 compared with those of other azoles against fluconazole resistant *Candida* spp. **Antimicrob Agent Chemother** 1995; 39: 868-871.
6. Duthie R, Denning DW. *Aspergillus* fungemia. Two cases and review. **Clin Infect Dis** 1995; 20: 598-605.
7. Denning DW. Can we prevent azole resistance in fungi? (Invited Commentary). **Lancet** 1995; 346: 454-455.
8. Denning DW, Evans EGV, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, Warnock DW, Warren RE). Fungal nail disease: a guide to good practice (Report of a Working Group of the British Society for Medical Mycology). **Br Med J** 1995; 311: 1277-1281.
9. Hopwood V, Evans EGV, Matthews J, Denning DW. *Scedosporium prolificans*, a multi-resistant fungus, from a UK AIDS patient. **J Infect** 1995; 30: 153-155.
10. Megson GM, Stevens DA, Hamilton JR, Denning DW. D-mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. **J Clin Microbiol** 1996;34:218-221.
11. Essayag SM, Burnie JP, Baily GG, Denning DW. Karyotyping of fluconazole-resistant yeasts reported on phenotype as *Candida krusei* or *Candida inconspicua*. **Intern J Syst Bacteriol** 1996;46:35-40.
12. Birch M, Robson G, Law D, Denning DW. Evidence of multiple phospholipase activities of *Aspergillus fumigatus*. **Infect Immun** 1996;64:751-755.
13. Law D, Moore CB, Joseph LA, Keaney MGL, Denning DW. High incidence of antifungal drug resistance in *Candida tropicalis*. **Int J Antimicrob Ag** 1996;7:241-245.
14. Wardle H, Law D, Denning DW. In vitro activity of pradimicin against fluconazole resistant *Candida* spp. **Antimicrobial Ag Chemoth** 1996; 40: 2229-2231.

15. Hood SV, Moore CB, Denning DW. The isolation of *Candida norvegensis* from clinical specimens: 4 case reports. **Clin Infect Dis**, 1996; 23: 1185-1187.
16. Law D, Sisson PR, Freeman R, Denning DW. Characterisation of *Aspergillus* by pyrolysis mass spectrometry. **Mycoses** 1996;39:433-436.
17. British Society for Antimicrobial Chemotherapy (Barnes RA, Denning DW, Evans EGV, Hay RJ, Prentice AG, Rogers TR, Speller DCE, Warnock DW, Warren RE) and the British Society for Medical Mycology (Denning DW, Evans EGV, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, Warnock DW, Warren RE). Fungal infections: a survey of laboratory services for diagnosis and treatment. **CDR Review** 1996; 6:R69-R75.
18. Carlson GL, Birch M, Mughal MM, Denning DW. *Aspergillus* wound infection following laparotomy. **J Infect** 1996; 33: 119-122.
19. Nho S, Anderson MJ, Moore CB, Denning DW. Species differentiation by internal transcribed spacer PCR and *HhaI* digestion of fluconazole-resistant *Candida krusei*, *Candida inconspicua* and *Candida norvegensis* strains. **J Clin Microbiol** 1997;35:1036-1039.
20. Denning DW, Venkateswarlu K, Oakley K, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL. Itraconazole resistance in *Aspergillus fumigatus*. **Antimicrob Ag Chemother** 1997; 41: 1364-1368.
21. Law D, Moore CB, Denning DW. Amphotericin B resistance testing of *Candida* spp: a comparison of methods. **J Antimicrob Chemother** 1997; 40: 109-112.
22. Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with amphotericin B and itraconazole against *Aspergillus* spp. **Antimicrob Ag Chemother** 1997;41:1124-1126.
23. Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of *Aspergillus fumigatus*. **Antimicrob Ag Chemother** 1997;41:1504-1507.
24. Baily GG, Moore CB, Essayag SM, de Wit S, Burnie JP, Denning DW. *Candida inconspicua*, a fluconazole resistant *Candida* species in HIV patients. **Clin Infect Dis** 1997;25:161-163.
25. Birch M, Drucker DB, Boote V, Denning DW. Prevalence of phthoic acid in *Aspergillus* spp. **J Med Vet Mycol** 1997;35:143-145.
26. Denning DW, Radford SA, Oakley K, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome for *Aspergillus fumigatus* infection. **J Antimicrob Chemother** 1997;40:401-414.
27. Law D, Moore CB, Denning DW. The activity of SCH 56592 compared with fluconazole and itraconazole against 100 azole resistant yeasts. **Antimicrob Ag Chemother** 1997;41:2310-2311.
28. Denning DW, Baily GG, Hood SV. Azole resistance in *Candida*. **Eur J Clin Microbiol Infect Dis** 1997;16: 261-280.
29. Verweij PE, Denning DW. Diagnostic and therapeutic strategies in invasive aspergillosis. **Sem Resp Crit Care** 1997;18:205-215.

30. Verweij PE, Denning DW. The challenge of invasive aspergillosis: Increasing numbers in diverse patient groups. **Int J Infect Dis** 1997;2:61-63.
31. British Society for Antimicrobial Chemotherapy Working Party on Fungal Infection (Barnes R, Denning DW, Evans EGV, Hay RJ, Prentice AG, Rogers TRF, Speller DCE, Warnock DW, Warren RE). Therapy of deep fungal infection in haematological malignancy. **J Antimicrob Chemother.**1997;40:779-788.
32. Hood SV, Moore CB, Cheesbrough JS, Mene A, Denning DW. Atypical eumycetoma caused by *Phialophora parasitica* successfully treated with itraconazole and flucytosine. **Br J Dermatol** 1997;136:953-956.
33. Hood SV, Moore CB, Denning DW. *Neurospora sitophila* pulmonary infection in a patient with AIDS. **AIDS Patient Care and STDs.** 1997; 11:219-222.
34. Takasuka T, Baily GG, Birch M, Anderson M, Law D, Denning DW. Variation in morphotype, karotype and DNA type in fluconazole resistant *C.albicans* from an AIDS patient. **J Infection** 1998;36:57-62.
35. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW. Efficacy of LY303366 against amphotericin B "susceptible" and "resistant" *A. fumigatus* infection in a murine model of invasive aspergillosis. **Antimicrob Ag Chemother** 1998; 42:873-878.
36. Oakley KL, Moore CB, Denning DW. The in vitro activity of voriconazole against *Aspergillus* spp. and comparison with amphotericin B and itraconazole. **J Antimicrob Chemother** 1998; 42: 91-94.
37. Oakley KL, Moore CB, Denning DW. *In vitro* activity of the echinocandin antifungal agent LY303,366 and comparison with itraconazole and amphotericin B against *Aspergillus* spp. **Antimicrob Ag Chemother** 1998; 42:2726-2730.
38. Verweij PE, Poulain D, Obayashi T, Patterson TF, Denning DW, Ponton J. Current trends in antigenemia metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. **Med Mycol** 1998; 36 (Suppl 1):146-155.
39. Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against *Aspergillus* species, with those of nystatin; amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. **Antimicrob Ag Chemother** 1999 43:1264-1266.
40. Oakley KL, Moore CB, Denning DW. Activity of pradimicin BMS-181184 against *Aspergillus* spp. **Int J Antimicrob Ag** 1999;12: 267-269.
41. Law D, Moore CB, Denning DW. Discrepancies associated with the measurement of itraconazole serum concentrations by bioassays (letter). **J Antimicrob Chemother,** 1999; 44: 577-578.
42. Johnson E, Oakley KL, Radford S, Moore CB, Warn P, Warnock DW, Denning DW. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome of in a murine model of *Aspergillus* infection. **J Antimicrob Chemother** 1999; 45: 85-93.
43. Denning DW. Early diagnosis of invasive aspergillosis. **Lancet** 2000; 355: 423-424.

44. Moore CB, Walls CM, Denning DW. In-vitro activity of the new triazole BMS-207147 against *Aspergillus* species and comparison with itraconazole and amphotericin B. **Antimicrob Ag Chemother** 2000; 2:441-3.
45. Moore CB, Sayers N, Mosquero J, Slaven J, Denning DW. Antifungal drug resistance in *Aspergillus*. **J Infection** 2000;41:203-220.
46. Warn PA, Morrissey J, Moore CB, Denning DW. In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant and fluconazole-sensitive *Candida tropicalis*. **Antimicrob Ag Chemother** 2000;44:2664-2671.
47. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against *Candida* species. **Clin Microbiol Infect** 2001;7:11-6.
48. Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. Susceptibility testing of *A. flavus*: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. **Antimicrob Ag Chemother** 2001;45:1456-62.
49. Wensch C, Moore CB, Krause R, Presterl E, Pichna P, Denning DW. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. **J Clin Microbiol** 2001;39:2458-62.
50. Heald A, O'Halloran DJ, Richards K, Webb F, Jenkins S, Denning DW, Young RJ. Fungal infection of the diabetic foot: Two distinct syndromes. **Diabetic Med** 2001;18:567-72.
51. Moore CB, Walls CM, Denning DW. In vitro activity of terbinafine against *Aspergillus* species and comparison with itraconazole and amphotericin B. **Antimicrob Ag Chemother** 2001;45:1882-5.
52. Mosquera J, Warn PA, Rodriguez-Tudela JL, Denning DW. Treatment of *Absidia corymbifera* infection in mice with amphotericin B and itraconazole. **J Antimicrob Chemother** 2001;48:583-6.
53. Mosquero J Denning DW. Azole cross resistance in *Aspergillus fumigatus*. **Antimicrob Ag Chemother** 2002;46:556-557.
54. Mosquero J, Sharp A, Moore CB, Warn PA, Denning DW. *In vitro* interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against *Aspergillus* spp. **J Antimicrob Chemother** 2002;50:189-94.
55. Moore CB, Walls CM, Denning DW. Comparison of three methods for *in vitro* susceptibility testing of *Candida* species with flucytosine. **J Antimicrob Chemother**. 2003;51:297-304.
56. Denning DW, Kibbler C, Barnes R. British Society for Medical Mycology proposed standards of care for invasive fungal infections. **Lancet Infect Dis** 2003;3:230-40.
57. Cuenca-Estrella M, Moore CB, Barchiesi F, Bille J, Chryssanthou E, Denning DW, Donnelly JP, Dromer F, Dupont B, Rex JH, Richardson MD, Sancak B, Verweij PE, Rodriguez-Tudela JL Multicentre Evaluation of the Reproducibility of the Proposed Antifungal Susceptibility Testing Method of the Antifungal Susceptibility Testing Subcommittee of The European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST). **Clin Microbiol Infect** 2003;9:467-74.

58. Cuenca-Estrella M, Moore CB, Barchiesi F, Bille J, Chryssanthou E, Denning DW, Donnelly JP, Dromer F, Dupont B, Rex JH, Richardson MD, Sancak B, Verweij PE, Rodriguez-Tudela JL and Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Document E-Dis 7.1. ESCMID. **Clin Microbiol Infect** 2003;9:i-viii.
59. Rodriguez-Tudela JL, Chryssanthou E, Petrikkou E, Mosquera J, Denning DW, Cuenca-Estrella M. Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. **J Clin Microbiol** 2003;41:5236-7.
60. Dodgson AR, Pujol C, Soll AJ, Denning DW, Fox AJ. Multilocus sequence typing (MLST) of *Candida glabrata* reveals geographically enriched clones. **J Clin Microbiol** 2003;41:5709-17.
61. Sambatakou H, Guiver M, Denning DW. Pulmonary aspergillosis in a patient with chronic granulomatous disease – diagnosis by PCR and successful treatment with voriconazole. **Eur J Clin Microbiol Infect Dis** 2003;22:681-5.
62. Warn PA, Sharp A, Guinea J, Denning DW. Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against *Aspergillus* and *Candida*. **J Antimicrob Chemother** 2004;53:743-9.
63. Hope WW, Padwell A, Guiver M, Denning DW. Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. **J Infection** 2004;49:136-40.
64. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to high concentrations of voriconazole. **Clin Infect Dis** 2004;39:1241-4.
65. Keevil B, Newman, Lockhart S, Moore CB, Howard SJ, Denning DW. Validation of an assay for voriconazole in serum samples using liquid chromatography- tandem mass spectrometry. **Ther Drug Monit** 2004;26:650-657.
66. Hope WW, Tabernero L, Denning DW, Anderson MJ. Insights into the molecular mechanisms of primary resistance to 5-fluorocytosine (5FC) in *Candida albicans*. **Antimicrob Ag Chemother** 2004; 48:4377-86.
67. Dodgson AR, Pujol C, Pfaller MJ, Denning DW, Soll DR. Evidence for recombination in *Candida glabrata*. **Fung Genet Biol** 2005;42:233-43.
68. Denning DW. Identification of common *Aspergillus* species, by MA Klich (Book review). **Mycopathologia** 2005;159:89.
69. Paoletti M, Rydholm C, Schwier EU, Anderson MJ, Szakacs G, Lutzoni F, Debeaupuis JP, Latgé JP, Denning DW, Dyer PS. Evidence for sexuality in the opportunistic fungal pathogen *Aspergillus fumigatus*. **Curr Biol** 2005;15:1242-8.
70. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. **Lancet Infectious Diseases** 2005;9:609-22.
71. Pasqualotto AC, Denning DW. Diagnosis of invasive fungal infections – current limitations of classical methods and new diagnostic methods. **Europ Oncol Rev** 2005; REV:1-11.

72. Woodcock AA, Steele N, Moore CB, Howard SJ, Custovic A, Denning DW. Fungal contamination of bedding. **Allergy** 2006;61:140-2.
73. Hamer EC, Moore CB, Denning DW. Comparison of two fluorescent whiteners, Calcofluor and Blankophor, in the detection of fungal elements in clinical specimens in the diagnostic laboratory. **Clin Microbiol Infect** 2006;12:181-4.
74. Warn PA, Sharp A, Denning DW. *In Vitro* Activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug) against *Aspergillus* spp. **J Antimicrob Chemother** 2006;57:135-8.
75. Hassan IA, Critten P, Isalska B, Denning DW. Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England. **J Clin Pathol** 2006;59:759-63.
76. Howard SJ, Walker SL, Andrew SM, Borman AM, Johnson EM, Denning DW. Subcutaneous phaeohyphomycosis caused by *Cladophialophora devriesii* in a United Kingdom resident. **Med Mycol** 2006;44:553-6.
77. Lass-Flörl C, Cuenca-Estrella M, Denning DW, Rodríguez-Tudela, JL. Antifungal susceptibility testing in *Aspergillus* spp. according to EUCAST methodology. **Med Mycol** 2006;44 (Suppl 1):319-25.
78. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW. Multi-azole resistance in *Aspergillus fumigatus*. **Int J Antimicrob Ag** 2006;28:450-3.
79. Hope WW, Drusano GL, Moore CB, Sharp A, Louie A, Walsh TJ, Denning DW, Warn PA. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. **Antimicrob Ag Chemother** 2007;51:285-295.
80. Rodríguez-Tudela JL, Donnelly JP, Pfaller MA, Chrystantou E, Warn P, Denning DW, Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M. Statistical analyses of correlation for fluconazole minimal inhibitory concentrations and *Candida* spp. for standard methodologies of EUCAST (E.Dis. 7.1) and CLSI (M27 A2). **J Clin Microbiol** 2007; 45:109-11.
81. Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in clinical failure and resistance. **Int J Antimicrob Ag** 2007;30:93-4.
82. Hedayati M, Pasqualotto A, Warn PA, Bowyer P, Denning DW. *Aspergillus flavus*: human pathogen, allergen and mycotoxin producer. **Microbiology** 2007;153:1677-92.
83. Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15-years experience from the United Kingdom. **J Antimicrob Chemother** 2007;59:791-3.
84. Arendrup MC, Denning DW. Does one voriconazole breakpoint suit all *Candida* species? **J Clin Microbiol** 2007;47:2093-4.
85. Hope WW, Warn PA, Sharp A, Reed P, Keevil B, Louie A, Walsh TJ, Denning DW, Drusano G. Optimization of the dosage of 5-fluorocytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. **Antimicrob Ag Chemother** 2007; 51:3760-2.
86. Pasqualotto AC, Shah M, Wynn R, Denning DW. Voriconazole plasma monitoring. **Arch Dis Child** 2008;93:578-81.

87. The European Committee on Antimicrobial Susceptibility Testing – Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Fegeler W, Gaustad P, Lass-Flörl C, Moore CB, Richardson M, Schmalreck A, Velegriaki A, Verweij P). EUCAST Technical Note on fluconazole. **Clin Microbiol Infect** 2008;14:193-195.
88. Rodriguez-Tudela JL, Arendrup M, Chryssanthou E, Dannaoui E, Denning DW, Donnelly JP, Schmalreck A, Verweij PE, Cuenca-Estrella M. Minimal inhibitory concentration distributions and epidemiological cut-offs of amphotericin B, flucytosine, fluconazole, itraconazole and voriconazole for *Candida* spp. using the EUCAST methodology for susceptibility testing. **Clin Microbiol Infect** 2008;14:982-4.
89. The European Committee on Antimicrobial Susceptibility Testing – Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Fegeler W, Gaustad P, Lass-Flörl C, Moore CB, Richardson M, Schmalreck A, Velegriaki A, Verweij P). EUCAST Technical Note on voriconazole. **Clin Microbiol Infect** 2008;14:985-7.
90. The European Committee on Antimicrobial Susceptibility Testing – Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Fegeler W, Gaustad P, Lass-Flörl C, Moore CB, Richardson M, Schmalreck A, Velegriaki A, Verweij P). EUCAST Technical Note on voriconazole. **Clin Microbiol Infect** 2008;14:985-7.
91. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. **Curr Op Infect Dis** 2008; 21: 580-8.
92. Duddy NE, Moore CB, Howard SJ, Denning DW. In vitro susceptibility of non-*Aspergillus* allergenic fungal species to azoles. **J Antimicrob Chemother** 2009. In press.